# US 2012/0251457 A1 · Methods and compositions for modulating adipocyte function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251457 A1
- Document ID: US20120251457A1
- Status: Published application
- Kind: A1
- Application number: 13/432,242
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2003-10-17
- Assignees: Children's Hospital Boston; Joslin Diabetes Center, Inc.
- Inventors: C. Ronald Kahn; Yu-Hua Tseng; Atul Butte
- Web page: https://patentgrep.com/patent/US20120251457A1

## CPC

- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 38/1709: {from mammals}
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/28: Insulins
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of identifying a candidate therapeutic agent for the treatment of obesity, the method comprising: providing a non-human animal model of obesity; administering to the animal one or more agent that increases the expression or activity of a member selected from the group consisting of: BMP-2, BMP-4, BMP-5, BMP-6 and BMP-7; and evaluating the effect of the one or more agent on obesity in the animal model, wherein an agent that decreases obesity in the animal model is a candidate therapeutic agent for the treatment of obesity.

### Claim 12 (depends on 11)

The method of claim 11, further comprising administering to the animal a second agent selected from the group consisting of BMP-1, BMP-3, PPARγ, Retinoid X receptor, alpha (RxRa), insulin, T3, a TZD, vitamin A, retinoic acid, glucocorticoid or agonist thereof, Wnt, IGF, EGF, FGF, TGFα, TGFβ, TNFα, VEGF and PDGF.

### Claim 13

(canceled)

### Claim 14 (depends on 11)

A method of decreasing fat stores or weight in a subject, the method comprising administering to the subject a therapeutically effective amount of a candidate therapeutic agent identified by the method of claim 11.

### Claim at position 6

15-18. (canceled)

### Claim 19

A method of decreasing fat stores or weight in a subject, the method comprising identifying a subject in need of decreasing fat stores or weight, and administering a composition to the subject, wherein the composition comprises a therapeutically effective amount of an agent that increases bone morphogenetic protein 7 (BMP-7) signaling, in an amount sufficient to promote BAT differentiation.

### Claim 20

A method of decreasing fat stores or weight in a subject, the method comprising identifying a subject in need of decreasing fat stores or weight, and administering a composition to the subject, wherein the composition comprises a therapeutically effective amount of one or more agent that increases signaling of a bone morphogenic protein selected from the group consisting of: (a) bone morphogenetic protein 2 (BMP-2); (b) bone morphogenetic protein 4 (BMP-4); (c) bone morphogenetic protein 5 (BMP-5); and (d) bone morphogenetic protein 6 (BMP-6), in an amount sufficient to promote BAT differentiation.

### Claim 21

A method of therapeutically and/or prophylactically treating obesity comprising identifying a subject in need of treating obesity, and administering a composition to the subject, wherein the composition comprises a therapeutically effective amount of one or more agent that increases signaling of a bone morphogenic protein selected from the group consisting of: (a) bone morphogenetic protein 2 (BMP-2); (b) bone morphogenetic protein 4 (BMP-4); (c) bone morphogenetic protein 5 (BMP-5); (d) bone morphogenetic protein 6 (BMP-6); and (e) bone morphogenic protein 7 (BMP-7), in an amount sufficient to promote BAT differentiation.

### Claim 22

A method for the therapeutically and/or prophylactically treating obesity comprising identifying a subject in need of treating and/or preventing obesity, and administering a composition to the subject, wherein the composition comprises a therapeutically or prophylactically effective amount of one or more agent that increases signaling of a bone morphogenic protein selected from the group consisting of: bone morphogenic protein 2 (BMP-2); bone morphogenic protein 4 (BMP-4); bone morphogenic protein 5 (BMP-5); bone morphogenic protein 6 (BMP-6); and bone morphogenic protein 7 (BMP-7).

### Claim 23

An in vitro method of promoting differentiation of preadipocyte or adipocyte cells into brown adipocyte tissue (BAT), the method comprising contacting a preadipocyte or adipocyte cell or tissue with one or more agent that increases signaling of a bone morphogenic protein selected from the group consisting of: bone morphogenic protein 2 (BMP-2); bone morphogenic protein 4 (BMP-4); bone morphogenic protein 5 (BMP-5); bone morphogenic protein 6 (BMP-6); and bone morphogenic protein 7 (BMP-7) in an amount sufficient to promote BAT differentiation; and evaluating BAT differentiation in the differentiated cell or tissue by measuring a marker of BAT differentiation.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method of claims 19-23, wherein the agent comprises a molecule selected from the group consisting of: (a) a BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 polypeptide; (b) a BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 nucleic acid; (c) an active fragment of (a) or (b); (d) an analog or variant of (a) or (b); (e) a peptide or protein agonist that increases the activity of BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7; (f) a small molecule or protein mimetic that mimics BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 signaling activity; (g) a small molecule that increases expression of BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 gene; (h) an antibody that binds to and stabilizes or assists the binding of BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 and/or BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 binding partner; and (i) a nucleotide sequence encoding a BMP-2, BMP-4, BMP-5, BMP-6 or BMP-7 polypeptide, or functional fragment or analog thereof.

### Claim 25 (depends on 19, 20, 21, 22, 23)

The method of claims 19-23, wherein the method further comprises administering a second agent selected from the group consisting of: BMP-1, BMP-3, PPARγ, Retinoid X receptor, alpha (RxRa), insulin, T3, TZD, vitamin A, retinoic acid, glucocorticoid or agonist thereof, Wnt, IGF, EGF, FGF, TGFα, TGFβ, TNFα, VEGF and PDGF.

### Claim 26

A method for providing a cell culture enriched in brown adipocytes, the method comprising: providing a plurality of preadipocyte or adipocyte cells in vitro; contacting the plurality of cells with a composition comprising one or more member selected from the group consisting of: (a) bone morphogenic protein 2 (BMP-2); (b) bone morphogenic protein 4 (BMP-4); (c) bone morphogenic protein 5 (BMP-5); (d) bone morphogenic protein 6 (BMP-6); and (e) bone morphogenic protein 7 (BMP-7), in an amount sufficient to promote BAT differentiation; and evaluating BAT differentiation in the culture, by measuring uncoupling protein-1 expression, wherein an increase in uncoupling protein-1 expression indicates an increase in BAT differentiation, thereby providing a culture enriched in brown adipocytes.

### Claim 27 (depends on 26)

The method of claim 26, wherein the preadipocyte or adipocyte cell or tissue comprises a white preadipocyte or white adipocyte.

### Claim 28 (depends on 26)

The method of claim 26, wherein the preadipocyte or adipocyte cell or tissue comprises a brown preadipocyte.

### Claim 29 (depends on 26)

The method of claim 26, wherein the level of BAT differentiation is further evaluated by measuring the level of a marker of BAT differentiation selected from the group consisting of PPAR-gamma Coactivator 1 (PGC-1), cytochrome oxidase activity, and mitochondrial DNA levels, wherein an increase in the level of the BAT marker indicates an increase in BAT differentiation.

### Claim 30 (depends on 19, 20)

The method of claim 19 or 20, wherein the medicament is administered to a site of adipose tissue.
